Salud financiera de hoja de balance de XOMA Royalty

Salud financiera controles de criterios 5/6

XOMA Royalty tiene un patrimonio de los accionistas total de $84.8M y una deuda total de $117.9M, lo que sitúa su ratio deuda-patrimonio en 139%. Sus activos y pasivos totales son $223.3M y $138.5M respectivamente.

Información clave

139.0%

Ratio deuda-patrimonio

US$117.92m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$142.84m
Patrimonio	US$84.81m
Total pasivo	US$138.53m
Activos totales	US$223.34m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($159.0M) de X0M1 superan a sus pasivos a corto plazo ($21.1M).

Pasivo a largo plazo: Los activos a corto plazo de X0M1 ($159.0M) superan a sus pasivos a largo plazo ($117.4M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: X0M1 tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de X0M1 ha crecido de 126.7% a 139% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: X0M1 tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: X0M1 tiene suficiente cash runway para más de 3 años si el flujo de caja libre sigue creciendo a tasas históricas de 16.7% cada año

Salud financiera de hoja de balance de XOMA Royalty

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Third quarter 2024 earnings released: US$1.59 loss per share (vs US$0.60 loss in 3Q 2023)

Insufficient new directors

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: EPS: US$1.37 (vs US$0.59 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.86 loss per share (vs US$0.98 loss in 1Q 2023)

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE).

XOMA Corporation, Annual General Meeting, May 15, 2024

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Corporation (NasdaqGM:XOMA) announces an Equity Buyback for $50 million worth of its shares.

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.60 loss per share (vs US$0.48 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.98 loss per share (vs US$0.32 loss in 1Q 2022)

Full year 2022 earnings released: US$1.50 loss per share (vs US$0.69 profit in FY 2021)

Investor sentiment improved over the past week

XOMA Corporation Appoints Owen Hughes as Interim Chief Executive Officer

Investor sentiment improved over the past week

Third quarter 2022 earnings released: US$0.48 loss per share (vs US$0.51 loss in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: US$0.53 loss per share (vs US$0.31 loss in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

XOMA Corporation(NasdaqGM:XOMA) dropped from Russell 2000 Dynamic Index

First quarter 2022 earnings released: US$0.32 loss per share (vs US$0.70 loss in 1Q 2021)

Investor sentiment deteriorated over the past week

XOMA Corporation, Annual General Meeting, May 18, 2022

Now 22% undervalued

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.098 loss in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: US$0.31 loss per share (vs US$0.33 loss in 2Q 2020)

CEO & Director recently sold €254k worth of stock

First quarter 2021 earnings released: US$0.70 loss per share (vs US$0.49 loss in 1Q 2020)

Full year 2020 earnings released: EPS US$0.82 (vs US$0.23 loss in FY 2019)

Revenue beats expectations

New 90-day high: €29.32

XOMA Earns First Milestone Payment from 2018 Royalty Purchase Agreement

Revenue misses expectations

Third quarter 2020 earnings released: US$0.098 loss per share

New 90-day high: €20.84

XOMA Corporation Earns $25 Million Milestone Payment

XOMA Corporation announced that it has received $1.4 million in funding from Rezolute, Inc.

New 90-day high: €17.92

XOMA Corporation to Report Q2, 2020 Results on Aug 06, 2020

Earnings released

New 90-day low - €14.03

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera